Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?
Limited evidence suggests that broad-spectrum fluoroquinolones such as gatifloxacin and moxifloxacin are more likely to cause Clostridium difficile-associated disease than levofloxacin. In a population-based case-control study of outpatients prescribed fluoroquinolones, we found no increased risk of C. difficile-associated disease requiring hospitalization among patients prescribed gatifloxacin or moxifloxacin compared to levofloxacin.
Dhalla
Irfan A
IA
Department of Medicine, Unversity of Toronto, Ontario M4E 3E9, Canada. irfan.dhalla@utoronto.ca
Mamdani
Muhammad M
MM
Simor
Andrew E
AE
Kopp
Alex
A
Rochon
Paula A
PA
Juurlink
David N
DN
D000368:Aged; D000369:Aged, 80 and over; D001372:Aza Compounds / Q000494:pharmacology; D016022:Case-Control Studies; D016360:Clostridioides difficile / Q000187:drug effects* / Q000302:isolation & purification; D004761:Enterocolitis, Pseudomembranous / Q000139:chemically induced* / Q000382:microbiology; D005260:Female; D024841:Fluoroquinolones / Q000494:pharmacology*; D000077734:Gatifloxacin; D006801:Humans; D064704:Levofloxacin; D008297:Male; D000077266:Moxifloxacin; D015242:Ofloxacin / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology
D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D064704:Levofloxacin; D015242:Ofloxacin; D000077734:Gatifloxacin; D000077266:Moxifloxacin